Thursday, February 27, 2025 / 3:00 PM - 4:00 PM EST
Topic: 2024 BBANYS Annual Meeting Winning Posters
Poster Title:
A 9-Year Assessment for the Impact of a Patient Blood Management Program on Red Blood Cell Usage
Presenter:
Ding Wen Wu, MD, PhD
Brief Bio:
Ding Wen Wu, MD, PhD is a Clinical Professor of Pathology at NYU Grossman School of Medicine, and the Medical Director for Department of Pathology and Laboratory Medicine, at NYU Langone Hospital- Brooklyn, in New York, US. She also holds several other positions at NYU Langone Health. In addition, she is the Medical Director of Blood Bank for SBH Health System, Bronx, New York.
Abstract:
The implementation of a patient blood management (PBM) program in 2013 and its full integration in 2014 at a New York City urban community teaching hospital aimed to improve blood transfusion practices through an organized, evidence-based multidisciplinary approach. The program’s objectives were to optimize patient care, minimize unnecessary red blood cell (RBC) transfusions, and improve patient outcomes. This study demonstrates that successful PBM can be achieved without allocation of significant additional resources or budgetary support through implementation of a few common-sense strategies.
______________
Poster Title:
Evaluation of the Procoagulant Properties of Platelet Modified Lysate in an Animal Model
Presenter:
Majed A. Refaai, MD
Brief Bio:
Dr. Refaai is a Professor of Pathology and Laboratory Medicine and Associate Director, Transfusion Medicine/Blood Bank at Strong Memorial Hospital, University of Rochester Medical Center, in Rochester, New York. He holds several other positions at this institution, including Director of the Thrombosis and Hemostasis Laboratory, Director of patient blood management program, Associate Director of the Automated Clinical Laboratory, and Associate Director of Therapeutic Apheresis, Internal Medicine at the Wilmot Cancer Center.
Abstract:
Platelet transfusions are commonly used in active bleeding, surgical or invasive medical procedures, prophylactically in thrombocytopenic patients, or in management of platelet disorders. Platelets adhere to the site of vessel wall damage following injury and form a platelet clot that will provide the binding sites for the activated coagulation factors and fibrin clots. Both in vivo and in vitro studies have shown that the activity seen in platelets is related to microparticles that shed during activation. As compared to the typical platelet products, the in vitro studies of our potential platelet modified lysate (PML) product (Patent #10,722,608) have revealed significantly higher platelet microparticles concentrations, increased thrombin generation, and greater overall procoagulant properties. We have demonstrated the extent of the procoagulant effect in pilot study murine models with both systemic and topical administration of the PML product.
Pricing:
- Members: FREE (Registration is required.)
- Non-Members: $45
To receive member pricing, be sure to sign in.
